ZA96994B - Method of treatment for decreasing mortality resulting from congestive heart failure. - Google Patents

Method of treatment for decreasing mortality resulting from congestive heart failure.

Info

Publication number
ZA96994B
ZA96994B ZA9600994A ZA96994A ZA96994B ZA 96994 B ZA96994 B ZA 96994B ZA 9600994 A ZA9600994 A ZA 9600994A ZA 96994 A ZA96994 A ZA 96994A ZA 96994 B ZA96994 B ZA 96994B
Authority
ZA
South Africa
Prior art keywords
treatment
heart failure
congestive heart
mortality resulting
decreasing mortality
Prior art date
Application number
ZA9600994A
Other languages
English (en)
Inventor
Mary Ann Lukas-Laskey
Robert Ruffolo Jr
Neil Shusterman
Gisbert Sponer
Klaus Strein
Original Assignee
Boehringer Mannheim Pharm Corp
Smith Kline Beecham Corp Ltd P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA96994(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by Boehringer Mannheim Pharm Corp, Smith Kline Beecham Corp Ltd P filed Critical Boehringer Mannheim Pharm Corp
Publication of ZA96994B publication Critical patent/ZA96994B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9600994A 1995-02-08 1996-02-08 Method of treatment for decreasing mortality resulting from congestive heart failure. ZA96994B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure

Publications (1)

Publication Number Publication Date
ZA96994B true ZA96994B (en) 1997-10-27

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9600994A ZA96994B (en) 1995-02-08 1996-02-08 Method of treatment for decreasing mortality resulting from congestive heart failure.

Country Status (26)

Country Link
US (6) US5760069A (cs)
EP (1) EP0808162B1 (cs)
JP (1) JP3546058B2 (cs)
KR (1) KR100295940B1 (cs)
CN (1) CN1093760C (cs)
AT (1) ATE179891T1 (cs)
AU (1) AU702106C (cs)
BR (1) BR9607111A (cs)
CA (1) CA2212548C (cs)
CZ (1) CZ292002B6 (cs)
DE (1) DE69602424T2 (cs)
DK (1) DK0808162T3 (cs)
ES (1) ES2134588T3 (cs)
FI (1) FI973255A7 (cs)
GR (1) GR3030966T3 (cs)
HU (1) HUP9900773A3 (cs)
NO (1) NO314830B1 (cs)
NZ (1) NZ301692A (cs)
PL (1) PL321737A1 (cs)
RO (1) RO121629B1 (cs)
RU (1) RU2197242C2 (cs)
SI (1) SI0808162T1 (cs)
SK (1) SK106897A3 (cs)
UA (1) UA55382C2 (cs)
WO (1) WO1996024348A2 (cs)
ZA (1) ZA96994B (cs)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
CA2267967A1 (en) * 1996-10-09 1998-04-16 Boehringer Mannheim Pharmaceuticals Corp. - Smithkline Beecham Corporati On Limited Partnership No.1 Method for inhibiting stress-activated protein kinases
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
WO1999024017A1 (en) * 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 Novel oral dosage form for carvedilol
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
CA2383974A1 (en) * 1999-09-08 2001-03-15 Nitromed Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
WO2001035961A1 (en) * 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
WO2002000216A1 (en) 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
JP2004525941A (ja) * 2001-04-02 2004-08-26 スミスクライン・ビーチャム・コーポレイション 治療方法
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
CA2462275A1 (en) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Novel composition of carvedilol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
EP1474133A4 (en) * 2002-01-15 2006-02-01 Teva Pharma SOLID CRYSTALLINE CARVEDILOL BODIES AND METHODS OF MAKING SAME
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
RU2203063C1 (ru) * 2002-03-12 2003-04-27 Нестерук Владимир Викторович Способ получения твердой лекарственной формы препарата, обладающего диуретическим действием
CA2483054A1 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US6951880B2 (en) * 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
JP2005533823A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法
ES2211846T3 (es) * 2002-07-25 2004-07-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Uso de cilobradina o sus sales farmaceuticamente aceptables para el tratamiento o la prevencion de la insuficiencia cardiaca.
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
EP1778267A4 (en) * 2004-07-16 2010-01-06 Nitromed Inc COMPOSITIONS AND METHODS ASSOCIATED WITH HEART FAILURE
KR20070088507A (ko) * 2005-06-09 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 카베딜올의 결정질 형태 및 이것의 제조 방법
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
CA2652135A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
EP2114881A1 (en) * 2007-02-26 2009-11-11 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
HUE025483T2 (en) 2008-05-16 2016-02-29 Corthera Inc Relaxin for use in the treatment of dyspnoea associated with acute heart failure
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
KR20140053307A (ko) 2011-08-12 2014-05-07 베링거잉겔하임베트메디카게엠베하 맛이 차폐된 약제학적 조성물
CA3027368A1 (en) * 2016-06-13 2017-12-21 Ascendia Pharmaceuticals, Llc Parenteral sustained-release delivery of carvedilol disperse systems
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
RU2058144C1 (ru) * 1988-12-15 1996-04-20 Центр по химии лекарственных средств Средство для лечения сердечной недостаточности
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
RU2032685C1 (ru) * 1991-12-16 1995-04-10 Центр по химии лекарственных средств Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
HK1014861A1 (en) 1999-10-08
HUP9900773A2 (hu) 1999-07-28
MX9706042A (es) 1998-06-30
US5760069A (en) 1998-06-02
EP0808162A2 (en) 1997-11-26
BR9607111A (pt) 1997-11-04
CZ246397A3 (cs) 1998-11-11
NO973667L (no) 1997-08-08
CA2212548A1 (en) 1996-08-15
HUP9900773A3 (en) 2000-04-28
CZ292002B6 (cs) 2003-07-16
WO1996024348A2 (en) 1996-08-15
CN1093760C (zh) 2002-11-06
AU4718196A (en) 1996-08-27
US5902821A (en) 1999-05-11
EP0808162B1 (en) 1999-05-12
US20030105138A1 (en) 2003-06-05
USRE40000E1 (en) 2008-01-08
JP3546058B2 (ja) 2004-07-21
RU2197242C2 (ru) 2003-01-27
USRE40707E1 (en) 2009-05-05
CA2212548C (en) 1999-08-24
WO1996024348A3 (en) 1996-10-03
ATE179891T1 (de) 1999-05-15
PL321737A1 (en) 1997-12-22
ES2134588T3 (es) 1999-10-01
SI0808162T1 (en) 1999-10-31
FI973255A0 (fi) 1997-08-07
DK0808162T3 (da) 1999-11-15
RO121629B1 (ro) 2008-01-30
US20010044455A1 (en) 2001-11-22
SK106897A3 (en) 1999-03-12
NZ301692A (en) 2000-09-29
KR100295940B1 (ko) 2001-08-07
KR19980702085A (ko) 1998-07-15
AU702106B2 (en) 1999-02-11
JPH10513463A (ja) 1998-12-22
UA55382C2 (uk) 2003-04-15
GR3030966T3 (en) 1999-11-30
FI973255A7 (fi) 1997-08-07
DE69602424D1 (de) 1999-06-17
NO314830B1 (no) 2003-06-02
DE69602424T2 (de) 1999-10-07
AU702106C (en) 2005-02-17
NO973667D0 (no) 1997-08-08
CN1185106A (zh) 1998-06-17

Similar Documents

Publication Publication Date Title
ZA96994B (en) Method of treatment for decreasing mortality resulting from congestive heart failure.
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
GEP20053470B (en) N-Heteroaryl-Pyridinesulfonamide Derivatives and Their Use as Endothelin Antagonists
SG49692A1 (en) Process for the production of a pharmaceutical agent for oral or topical administration in the treatment of leishmaniasis
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
EP0746313A4 (en) METHOD FOR TREATING SMALL Mouth Ulcers
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
PL322284A1 (en) Derivatives of aminoteralin useful in treating diseases of cardiovascular system
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
IL101163A (en) Use of flunarizine in the preparation of medicaments for treating neoplastic diseases
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
IL151878A0 (en) Pharmaceutical compositions containing t3
AU3673795A (en) Preventive and remedy for diarrhea
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
UA22017A (uk) Спосіб іhтеhсифікації еhергетичhого обміhу
GR3031908T3 (en) Novel 17-hydroxyiminoalkyl and 17-hydroxyiminomethylalkenyl cyclopentaneperhydrophenanthrene derivatives active on the cardiovascular system, a process for their preparation and pharmaceutical compositions containing same
FR2646348B1 (cs)
EP0576913A3 (en) Digitoxigenin and dihydrodigitoxigenin 3-beta derivatives and pharmaceutical preparations thereof, for the treatment of cardiovascular diseases.
UA23363A (uk) Спосіб лікування запальних процесів придатків матки
UA35912A (uk) Спосіб лікування виразкової хвороби шлунку та дванадцятипалої кишки
UA16000A1 (uk) Спосіб лікуваhhя гіпотрофії поросят
UA23364A (uk) Спосіб лікування гострого ендометриту
MX9709163A (es) El uso de un compuesto potenciador de dopamina/reductor de prolactina para preparar composiciones para prevenir la estenosis asociada con intervencion despues de intervenciones invasivas sin derivacion.
UA10234A (uk) Спосіб лікування цукрового діабету